Magnetic Chemiluminescence Gastrin-17 Detection Kit
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting gastrin-17, such as enzyme-linked immunosorbent assay (ELISA), are inefficient, prone to manual errors, and have low specificity and sensitivity due to long detection times and susceptibility to external disturbances, and existing methods for full-fragment gastrin detection using radioimmunoassay (RIA) and chemiluminescence immunoassay (CLIA) face challenges in clinical disease testing and diagnosis due to complex composition and reduced specificity and sensitivity.
Innovation Solution
A kit utilizing specific binding of gastrin-17 to anti-gastrin-17 antibodies combined with luminescent properties and magnetism of magnetic spheres, allowing for accurate determination of gastrin-17 content through chemiluminescence immunoassay using a double antibody sandwich or competition mechanism, which reduces manual operational errors and enhances sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If enzyme-linked immunosorbent assay (ELISA) is used for detecting gastrin-17, then the detection method is simple and widely used, but the detection time is long and the sensitivity and specificity are low
Solution Approach 1:
The patent replaces the traditional ELISA mechanical/chemical reaction system with a magnetic field-based separation system. Magnetic spheres coated with antibodies are used to capture gastrin-17, and the bound complex is separated from the sample using an external magnetic field. This substitution dramatically reduces detection time while maintaining ease of operation, as the magnetic separation is rapid and does not require lengthy incubation or washing steps associated with ELISA
Solution Approach 2:
The patent changes the detection parameters by using chemiluminescence labeling instead of traditional ELISA colorimetric detection. The trace marker (chemiluminescent label) provides a signal that is significantly more sensitive and specific than ELISA, allowing for rapid detection with improved accuracy. This parameter change from colorimetric to chemiluminescent detection resolves the contradiction between simplicity and performance
2Ease of manufacture
If enzyme-linked immunosorbent assay (ELISA) is used for detecting gastrin-17, then the detection method is simple and widely used, but the sensitivity and specificity are low due to susceptibility to external disturbances
Solution Approach 1:
The patent replaces the ELISA system with a magnetic chemiluminescence immunoassay system. The magnetic spheres provide stable, reproducible binding, and the chemiluminescence detection is not susceptible to the external disturbances (such as color interference, pH variations, and temperature fluctuations) that affect ELISA. This substitution maintains operational simplicity while dramatically improving reliability and resistance to external disturbances
Solution Approach 2:
The patent introduces magnetic spheres as an intermediary carrier between the antibody and the detection system. These magnetic spheres provide a stable platform for antibody attachment and sample binding, isolating the detection system from external disturbances. The magnetic field acts as a clean separation mechanism that does not introduce the variability inherent in ELISA protocols, thereby improving specificity and sensitivity
3Measurement precision
If radioimmunoassay (RIA) and chemiluminescence immunoassay (CLIA) are used for full-fragment gastrin detection, then the detection sensitivity is high, but the complex composition reduces specificity and diagnostic accuracy
Solution Approach 1:
The patent extracts and detects only the clinically relevant gastrin-17 fragment (1-17 amino acids) using antibodies specifically targeted to this sequence. By focusing detection on this specific fragment rather than attempting to detect all gastrin forms, the assay achieves both high sensitivity for gastrin-17 and high specificity for clinical diagnosis of atrophic gastritis and gastric cancer risk
Solution Approach 2:
The patent applies local quality by using antibodies with high specificity for the gastrin-17 sequence. The first antibody (capture antibody) and second antibody (detection antibody) are both specifically designed to bind to epitopes within the gastrin-17 molecule, ensuring that only this specific fragment is detected. This localized specificity resolves the contradiction by maintaining high sensitivity while eliminating cross-reactivity with other gastrin forms that would reduce diagnostic accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The kit significantly shortens detection time, improves accuracy, and increases sensitivity and specificity for gastrin-17 detection, facilitating rapid and reliable clinical diagnosis by using magnetic spheres and trace markers for enhanced chemiluminescence immunoassay.
Implementation Method 1
labeled with a trace marker... luminescent properties of trace marker... allowing for accurate determination of gastrin-17 content through chemiluminescence immunoassay
Implementation Method 2
coated on a magnetic sphere... combined with luminescent properties and magnetism of magnetic spheres
Data Source
AI summary
A reagent kit used for detecting gastrin-17, a preparation method, and a detection method for the reagent kit. The reagent kit comprises component A and component B, wherein component A is a first anti-gastrin-17 antibody marked with a trace marker or coated on magnetic spheres, and component B is a second gastrin-17 antibody or gastrin-17 coated on magnetic spheres or marked with a trace marker. Either one of component A and component B is marked with the trace marker, and the other one is coated on the magnetic spheres. The first gastrin-17 antibody and gastrin-17 binding site is different from the second gastrin-17 antibody and gastrin-17 binding site. The method using a double antibody sandwich method or a competition method to detect gastrin-17 accurately and sensitively measures the amount of gastrin-17 in a sample.